Dr. David C. Chua, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Years since graduation
- 46
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 596
Licensed in Illinois since 1984, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
IL license 036069933 (first issued 1984; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Presence Saints Mary and Elizabeth Medical Center Chicago, IL
- Humboldt PArk Health Chicago, IL
Medical groups
- Humboldt PArk Health (110 clinicians)
- David C Chua MDsc LTD (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 596
- Services billed
- 1,222
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 564 | 379 |
| Established patient office or other outpatient visit, 20-29 minutes | 143 | 134 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 136 | 71 |
| New patient office or other outpatient visit, 45-59 minutes | 129 | 129 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 47 | 42 |
| Biopsy of large bowel using a flexible endoscope | 44 | 44 |
| New patient office or other outpatient visit, 30-44 minutes | 35 | 35 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 26 | 26 |
| Telephone medical discussion with physician, 11-20 minutes | 25 | 25 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 20 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoclopramide Hcl Other prescribers in Oakbrook Terrace, IL | 985 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Oakbrook Terrace, IL | 450 |
| Omeprazole Other prescribers in Oakbrook Terrace, IL | 395 |
| Lansoprazole Other prescribers in Oakbrook Terrace, IL | 298 |
| Pantoprazole Sodium Other prescribers in Oakbrook Terrace, IL | 286 |
| Linzess (linaclotide) Other prescribers in Oakbrook Terrace, IL | 176 |
| Dexlansoprazole Dr (dexlansoprazole) Other prescribers in Oakbrook Terrace, IL | 109 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Oakbrook Terrace, IL | 97 |
| Gavilyte-C (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Oakbrook Terrace, IL | 88 |
| Peg 3350-Electrolyte (sodium chloride/nahco3/kcl/peg) | 61 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $31.79 in total to this clinician.
| Celltrion USA Inc. | $16.91 |
|---|---|
| AbbVie Inc. | $14.88 |
| Food and Beverage | $31.79 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,000 in research payments for these studies, mostly to the institutions running them.
- A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Eli Lilly and Company · Completed · NCT03926130
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.